Carregant...
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma
Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma characterized by short survival with current therapies, emphasizing the urgent need to develop new therapeutic approaches. Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal antibody (cAC10) conjugated by a proteas...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3744990/ https://ncbi.nlm.nih.gov/pubmed/23838350 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-481713 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|